Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Q4 Revenues Up on Commericialization of Genotyping Systems

NEW YORK, Feb 15 – Variagenics said Thursday its fourth-quarter revenues jumped to $1.2 million, compared with $100,000 in the previous year while revenues for the year rose to $2.3 million from $400,000.

"The year 2000 was pivotal for Variagenics as we commercialized our proprietary technologies for identifying drug-specific genetic markers," Taylor Crouch, CEO of Variagenics, said in a statement. "We are pursuing a vision to place Variagenics' pharmacogenomics at the heart of a new generation of individualized drugs and companion diagnostics.”

Fourth-quarter net losses excluding non-cash equity compensation was $1.8 million, or eight cents a diluted share, compared with $2.3 million, or $3.20 a diluted share, in the year ago period.

For the year, net losses excluding non-cash equity compensation totaled $9.2 million, or 85 cents a diluted share, compared with $13.7 million, or $22.65 a diluted share, in 1999.

The company ended the year with $99.0 million in cash and marketable securities.

During the year, Variagenics of Cambridge, Mass., launched a custom DNA analysis platform, known as NuCleave, and licensed its first system to Covance Central Laboratories Services. The system combines Variagenics' chemical cleavage genotypying and haplotying technologies, Bruker Daltonics' mass spectrometry, Hamilton's robotics, and Waters' DNA sample purification technology.

Waters gave Variagenics $3.0 million in cash in July and made an equity investment in the company for $7.5 million in common stock. Variagenics received a milestone payment from Waters following the sale of the NuCleave system to Covance.

In 2000, the company also expanded its genetic marker database for use in the drug discovery process. The company has patent filings on some 30,000 genetic markers.

So far in 2001, Variagenics has announced deals with Amgen and Isis Pharmaceuticals.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.